Pricing
  1. US-listed companies
  2. U.S. Stem Cell, Inc.
  3. Financials
  4. EBITDA margin (%)

U.S. Stem Cell, Inc.【USRM】

Market cap
$64.15K
P/E ratio
SummaryFinancials
Period EndEBITDA margin (%) YoY (%)
Dec 31, 2020-866.2+6416.36%
Dec 31, 2018-13.3+17.24%
Dec 31, 2017-11.3-69.70%
Dec 31, 2016-37.4-68.47%
Dec 31, 2015-118.7-30.79%
Dec 31, 2014-171.5+21.23%
Dec 31, 2013-141.4+9.70%
Dec 31, 2012-128.9-12.59%
Dec 31, 2011-147.5

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)